홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
TNGX
#1968
Tango Therapeutics, Inc.
11.1
4
+0.81%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+0.81%
월간 변동
-7.32%
6달 변화
+60.75%
년간 변동율
+413.36%
이전 종가
11.0
5
Open
11.1
4
Bid
Ask
Low
11.1
4
High
11.1
4
양
136
마켓
주식
헬스케어
TNGX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
21.38 M
87.71 M
88.2 M
106.72 M
108.11 M
—
Valuation ratios
Enterprise value
—
816.78 M
584.8 M
998.66 M
264.52 M
1.96 B
Price to earnings ratio
—
—
-5.94
-9.24
-2.6
-16.88
Price to sales ratio
—
—
25.82
25.84
8.02
49.37
Price to cash flow ratio
—
—
5.89
8
2.57
13.89
Price to book ratio
—
—
2.57
3.73
1.69
4.06
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
0.12
0.25
0.25
0.41
0.5
Return on equity %
—
0.17
0.43
0.4
0.65
0.82
Return on invested capital %
—
222.86
607.53
467.38
700.51
734.75
Gross margin %
—
100
100
100
100
400
Operating margin %
—
157.09
446.79
312.57
346.09
3 096.7
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
157.21
435.14
278.54
309.73
2 905.68
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
13.1
12.1
6.76
7.54
6.98
26.87
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
0.11
0.05
0.09
0.12
0.28
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.24
1.25
1.2
1.31
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.66
6.42
2.36
7.26
Net current asset value per share
—
—
4.27
3.66
2.44
7.59
Tangible book value per share
—
—
2.84
2.68
1.83
5.92
Working capital per share
—
—
3.64
3.18
2.09
6.39
Book value per share
—
—
2.84
2.68
1.83
5.92
뉴스
스티펠, 탱고 테라퓨틱스에 ’매수’ 등급 재확인
Stifel reiterates Tango Therapeutics stock rating at Buy
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Tango Therapeutics, 52주 신고가 경신: 13.5 USD
Tango Therapeutics stock hits 52-week high at 13.5 USD
미주호, Tango Therapeutics에 ’아웃퍼폼’ 등급 개시
Mizuho initiates Tango Therapeutics stock with outperform rating
Tango Therapeutics, 52주 신고가 경신, 주당 $13.47
Tango Therapeutics stock hits 52-week high at $13.47
Tango Therapeutics CFO, TNGX 주식 126,530달러 매도
Tango Therapeutics CFO sells $126,530 in TNGX stock
탱고 테라퓨틱스 이사, TNGX 주식 37만 4천 달러 매도